

27 **ABSTRACT**

28

29 **Background.** Fever is a common presenting symptom in low- and middle-income countries (LMICs). 30 It was previously assumed that malaria was the cause in such patients, but its incidence has declined 31 rapidly. The urgent need to develop point-of-care tests for the most important causes of non-32 malarial acute febrile illness is hampered by the lack of robust epidemiological data. We sought to 33 obtain expert consensus on analytes which should be prioritized for inclusion in fingerprick blood-34 based multiplex lateral flow rapid diagnostic tests (LF-RDTs) targeted towards four categories of 35 patients with acute non-malarial fever in South and Southeast Asian LMICs, stratified by age 36 (paediatric vs. adult) and care setting (primary vs. secondary care). 37 **Methodology/Principal Findings.** We conducted a two-round modified e-Delphi survey. A total of 84 38 panellists were invited, consisting of seven each from 12 countries, divided into three regional 39 panels (Mainland Southeast Asia, Maritime Southeast Asia, and South Asia). Panellists were asked to 40 rank their top seven analytes for inclusion in LF-RDTs to be used in each patient category, justify 41 their choices, and indicate whether such LF-RDTs should be incorporated into algorithm-based 42 clinical decision support tools. Thirty-six panellists (43%) participated in the first round and 44 (52%) 43 in the second. There was consensus that such LF-RDTs should be incorporated into clinical decision 44 support tools. At a minimum, these LF-RDTs should be able to diagnose dengue and enteric fever in 45 all patient categories. There was a clear preference to develop LF-RDTs for pathogens not readily 46 detected by existing technologies, and for direct diagnosis through antigen detection. Pathogen 47 biomarkers were prioritized over host inflammatory biomarkers, with CRP being the only one ranked 48 consistently highly. 49 **Conclusions/Significance.** Our results provide guidance on prioritizing analytes for inclusion in 50 context-specific multiplex LF-RDTs and similar platforms for non-malarial acute febrile illness, for

51 which there is an urgent unmet need.

52 **AUTHOR SUMMARY**

53

54 In rural South and Southeast Asia, most acute febrile illness was previously attributable to malaria 55 but the incidence of malaria is declining. To aid diagnosis and prognosis in patients presenting with 56 the common symptom of acute fever with no localising features but in whom malaria has been 57 excluded, there is an urgent need to develop minimally-invasive rapid diagnostic tests (RDTs) which 58 can test for multiple pathogen and host biomarkers. Obtaining expert consensus opinions on what 59 biomarkers these tests should detect will contribute greatly to their development, but there is a 60 paucity of robust epidemiological data on the diverse non-malarial causes of acute fever. We 61 determined the biomarkers which should be included in region-specific fingerprick blood-based RDTs 62 tailored to four patient categories differentiated by age and level of care, in the form of seven-item 63 lists ranked in decreasing order of priority. To provide context for these rank lists, we ascertained 64 the principal factors influencing expert priority-setting and explored perceptions of the clinical utility 65 of such RDTs. Our results provide essential region-specific guidance to aid development of RDTs for 66 acute non-malarial fever, for which there was strong consensus for their inclusion in clinical decision-67 making tools for low- and semi-skilled healthcare staff.

68 **INTRODUCTION**

69

70 Fever is a common but non-specific sign of sepsis.[1] In regions with high burdens of infectious 71 diseases such as South and Southeast Asia, many patients present acutely with fever but without 72 localising signs and symptoms. It was previously assumed that malaria was the cause in most 73 patients presenting with such fevers, but the roll-out of highly accurate malaria rapid diagnostic tests 74 along with the success of public health efforts to eradicate malaria has resulted in a large decline in 75 malaria incidence.[2, 3] Febrile illnesses, however, are still a common cause for seeking medical care 76 in rural communities and, while early intervention is crucial in the management of sepsis, obtaining 77 clinical and/or microbiological diagnoses is difficult in these resource-poor settings. 78 79 Fingerprick blood-based rapid diagnostic tests for several other infectious diseases based on lateral 80 flow technology e.g., HIV and Ebola virus disease, have been developed and rolled out in both high-81 and low-resource settings.[4, 5] These are generally immunoassays based on the detection of 82 microbial antigens and/or antibodies against the causative pathogens, although nucleic acid-based 83 assays have more recently been developed.[6] Similar to these pathogen biomarker assays, tests for 84 several host inflammatory biomarkers of potential diagnostic and/or prognostic significance are also 85 available.[7] The test kits comprise of a recognition layer containing the detection sites, combined 86 with a porous membrane which draws the fluid to be tested past the detection sites by capillary 87 action.[8] They are low-cost, simple to operate, require no specialised equipment, and can be used 88 at the point of care, returning results in 30 minutes or less, thus making them ideal for use in low-89 resource settings.[9, 10]

90

91 These features, along with the endemicity of myriad infectious diseases in the region, poorly trained 92 health workforce, and lack of diagnostic microbiology capability create a pressing need for multiplex 93 lateral flow rapid diagnostic test kits (LF-RDTs) for multiple infections to guide patient management

94 with the minimum amount of test substrate. The use of multiple single-disease LF-RDTs is unlikely to 95 be cost-effective or logistically feasible, and is sub-optimal for patient comfort. However, 96 ascertainment of the most important infective aetiologies of fever to aid the development of 97 relevant multiplex LF-RDTs and other diagnostic tools in South and Southeast Asia is hampered by 98 the paucity of reliable epidemiological data covering not just incidence, but also disease burden in 99 terms of morbidity and mortality.[11] There is, thus, a high degree of uncertainty in prioritization of 100 pathogens for inclusion in such tests; furthermore, what little published evidence there is comes 101 mainly from cities, rather than rural areas where most of the population live.[12] In addition, there is 102 growing interest in augmenting pathogen-based diagnostics by assaying host biomarkers of 103 inflammation in parallel, in particular those which can assist in the differentiation viral from non-viral 104 infections, thus improving antimicrobial stewardship,[13] or predict or indicate severe disease, thus 105 improving the identification of patients who require escalation of care.[14] 106 107 Given the poor understanding of the epidemiology of febrile illness in South and Southeast Asia, we 108 conducted a modified e-Delphi survey to obtain expert consensus on pathogen-specific and host 109 inflammatory biomarker analytes which should be prioritized for inclusion in multiplex LF-RDTs with 110 fingerprick blood as the test substrate, for use in acutely febrile rural residents of South and 111 Southeast Asian low- and middle-income countries (LMICs) who test negative for malaria and in 112 whom the source of infection is unclear. We also aimed to explore the reasoning and contextual 113 background underlying the selection of these analytes.

114 **METHODS**

115

140

141 *First round*

142

165 90% across all targets helpful to guide clinical decision-making, and whether they would recommend

166 its inclusion in electronic algorithm-based clinical decision support tools for use in their countries. 167 Finally, to provide further context, participants were asked to rank what they perceived to be the 168 five commonest causes of acute febrile illness in their regions in terms of annual incidence. 169 Consensus was achieved if ≥80% of the participants for each region agreed on a particular response. 170 Questions for which consensus was achieved in the first round were not repeated. 171 172 At the conclusion of the first round, participants were invited to provide free-text feedback on the 173 survey structure and questions. Free-text suggestions for improvement were analysed thematically 174 and used to inform the subsequent iteration of the questionnaire. Changes were made based on the 175 number of times an issue was raised, the practicality of the suggested change, and its relevance to 176 the context of the survey. 177 178 *Second round* 179 180 All panellists were re-invited to participate in the second round run two weeks after the end of the 181 first, unless they explicitly declined to participate in the first round. The latter (n=10) were replaced 182 in the second round, while maintaining the gender and clinician balance described previously. 183 184 In this round, only options that had been selected in the first round for each scenario were included. 185 First-round respondents who participated in the second round were shown their previous answers 186 to each question. To assist participants in reaching consensus, the frequencies of every analyte 187 selected in each rank position, along with their sum of weighted scores, were shown graphically. An 188 analyte ranked first was assigned a weighted score seven times more than if it was ranked last. 189 Similarly, for the question on the commonest causes of acute febrile illness, an aetiology ranked first 190 was assigned a weighted score five times more than if it was ranked last. The factors influencing

- 191 participant reasoning for their rankings from the first round were analysed thematically and
- 192 presented as discrete options in this round.

193

- 194 In the event that consensus for each rank position was unable to be reached by the end of the
- 195 second round, agreement was quantified by constructing rank lists of the seven highest-scoring
- 196 analytes for each scenario and of the five highest-scoring aetiologies of febrile illness were

197 constructed.

- 198
- 199 Statistical analyses were performed using Microsoft Excel (Microsoft, Washington, USA).

200 **RESULTS**

201

223

248

249 The only host inflammatory biomarker which featured prominently in this survey was C-reactive 250 protein (CRP). CRP was included in all rank lists except those for adult secondary care in Mainland 251 and Maritime Southeast Asia (Figures 1–3). However, it was most frequently found in the bottom 252 half of rank lists, indicative of the majority opinion that host biomarkers are less useful than 253 microbiological diagnosis (Figure 5). 254 255 Furthermore, while twenty-eight (64%) respondents across all panels ranked CRP in one or more 256 scenarios, there was little agreement on use case. Eight (29%) believed it was a good discriminator 257 between viral and non-viral infections in all scenarios in which CRP featured in their rank lists, while 258 two (7%) believed it to be a good marker of disease severity. A further eight (29%) thought CRP was 259 able to fulfil both use cases, while 10 (36%) were of the opinion that use case varies depending on 260 patient age and care setting. 261 262 For the scenario-based questions, the top-ranked three analytes in each rank list were unchanged 263 between the first and second rounds although their individual positions varied slightly, except for 264 the Maritime Southeast Asia and South Asia adult secondary care rank lists where the top-ranked 265 two analytes were constant between rounds. The top-ranked analyte in all rank lists in the first

266 round was either dengue NS1 antigen or typhoidal *Salmonella* antigen, demonstrating a degree of 267 convergence at the end of the survey as both these analytes occupied the top two positions in all 268 lists in the second round. The top three perceived aetiologies of acute febrile illness in all regions

269 were also unchanged between rounds.

270

271 **Table 1.** Regional panel participant demographic and professional background details.

272 **DISCUSSION**

273

274 The results of this survey indicate that multiplex LF-RDTs for non-malarial acute febrile illness to be 275 developed for use in South and Southeast Asia should be able to diagnose dengue and enteric fever 276 in all age groups and care settings. There was also a clear desire for the development of LF-RDTs for 277 pathogens not readily detected by existing technologies, and for these new tests to diagnose 278 diseases directly through antigen detection. Pathogen biomarkers were prioritized over host 279 biomarkers, for which the only contender for inclusion was CRP although there was little agreement 280 on use case. The majority of the other pathogen biomarkers selected reflect the almost equal 281 consideration given to clinical and epidemiological burdens of disease. Importantly, there was strong 282 and early consensus that such LF-RDTs would aid clinical decision-making and that they should be 283 incorporated into algorithm-based clinical decision support tools.

284

285 Our study has several strengths. Firstly, the modified Delphi method is well-suited to address the 286 research question, given the challenges in collecting comprehensive epidemiological data before 287 commencing work on LF-RDT development. The Delphi survey is a well-established technique 288 facilitating consensus decision-making and avoiding domination by individual experts, as it is 289 anonymous, systematic, iterative, and inclusive of a range of opinions.[19, 20] Secondly, we adhered 290 to best practice by pre-specifying the consensus definition, panellist selection criteria, and closing 291 criterion, and by providing timely, well-structured controlled feedback.[21, 22] In addition, we 292 ensured generalizability through assembling appropriately-sized panels of suitably qualified 293 members from diverse backgrounds and countries,[21] and by taking steps to ensure that the 294 response rate for each panel exceeded the approximately 30% response rate typical of online 295 surveys.[23] Thirdly, the participant retention rate between the two rounds was high. However, by 296 re-inviting panellists who did not participate in the first round, we avoided the possibility of false 297 consensus and ensured optimal representation of perspectives.[24] Fourthly, although response

298 stability was not a closing criterion, the consistency of the top-ranked two to three responses to 299 each question between rounds is indicative of the reliability of our results.[22, 25]

300

301 The principal weakness of our study is that consensus, as per the prespecified definition, was not

302 reached with regard to analyte rankings. However, we had anticipated this possibility and, thus,

303 prespecified an alternative method of analyte prioritisation based on sums of weighted scores.

304 Secondly, for pragmatic reasons we only surveyed experts from 12 out of the 15 LMICs in South and

305 Southeast Asia. However, because panellist selection was weighted towards large countries both in

306 terms of area and population, our results are still likely to be of considerable benefit in informing the

307 development of LF-RDTs to be used in these regions.

308

309 Our results complement and extend previous work by Osborn et al. which, to our knowledge, is the 310 only other study which has attempted to address this important question. They conducted a global 311 prioritization exercise for a cartridge-based diagnostic test for pathogens causing severe febrile 312 illness without a known source in patients presenting to secondary care.[26] Unlike their study, ours 313 concentrated on acute non-malarial fever in both primary and secondary care settings with patients 314 stratified by age, included host inflammatory biomarkers as options, and adopted a more granular 315 regional focus. Both studies had typhoidal *Salmonella* as a top priority pathogen in addition to 316 leptospirosis and rickettsioses, but we also recognized dengue and melioidosis as other major 317 priorities given our emphasis on rural South and Southeast Asia. Additionally, for each pathogen we 318 explored what participants deemed the ideal analyte, as well as the motivations and reasoning 319 behind their choices. Our findings, therefore, add further layers of context which are essential to 320 ensuring acceptability and applicability, two key challenges facing the development and 321 implementation of any such LF-POCTs developed for use in these regions.[27]

322

363 **REFERENCES**

364

365 1. Rampersad A, Mukundan D. Fever. Curr Opin Pediatr. 2009;21(1):139-44. doi:

366 10.1097/MOP.0b013e32832130d2.

367 2. Mukkala AN, Kwan J, Lau R, Harris D, Kain D, Boggild AK. An Update on Malaria Rapid

368 Diagnostic Tests. Curr Infect Dis Rep. 2018;20(12):49. doi: 10.1007/s11908-018-0655-4.

369 3. Oyegoke OO, Maharaj L, Akoniyon OP, Kwoji I, Roux AT, Adewumi TS, et al. Malaria

370 diagnostic methods with the elimination goal in view. Parasitol Res. 2022;23(1):1-19. doi:

371 10.1007/s00436-022-07512-9.

372 4. Wongkanya R, Pankam T, Wolf S, Pattanachaiwit S, Jantarapakde J, Pengnongyang S, et al.

373 HIV rapid diagnostic testing by lay providers in a key population-led health service programme in

374 Thailand. J Virus Erad. 2018;4(1):12-5.

375 5. Wonderly B, Jones S, Gatton ML, Barber J, Killip M, Hudson C, et al. Comparative

376 performance of four rapid Ebola antigen-detection lateral flow immunoassays during the 2014-2016

377 Ebola epidemic in West Africa. PLoS One. 2019;14(3):e0212113. doi: 10.1371/journal.pone.0212113.

378 6. Liu T, Choi G, Tang Z, Kshirsagar A, Politza AJ, Guan W. Fingerpick Blood-Based Nucleic Acid

379 Testing on A USB Interfaced Device towards HIV self-testing. Biosens Bioelectron. 2022;209:114255.

380 doi: 10.1016/j.bios.2022.114255.

381 7. Teggert A, Datta H, Ali Z. Biomarkers for Point-of-Care Diagnosis of Sepsis. Micromachines 382 (Basel). 2020;11(3):286. doi: doi: 10.3390/mi11030286.

383 8. Anfossi L, Di Nardo F, Cavalera S, Giovannoli C, Baggiani C. Multiplex Lateral Flow

384 Immunoassay: An Overview of Strategies towards High-throughput Point-of-Need Testing.

385 Biosensors (Basel). 2018;9(1):2. doi: 10.3390/bios9010002.

386 9. Posthuma-Trumpie GA, Korf J, van Amerongen A. Lateral flow (immuno)assay: its strengths,

387 weaknesses, opportunities and threats. A literature survey. Anal Bioanal Chem. 2009;393(2):569-82.

388 doi: 10.1007/s00216-008-2287-2.

389 10. Chappuis F, Alirol E, d'Acremont V, Bottieau E, Yansouni CP. Rapid diagnostic tests for non-

390 malarial febrile illness in the tropics. Clin Microbiol Infect. 2013;19(5):422-31. doi: 10.1111/1469-

391 0691.12154.

392 11. Newton PN, Guerin PJ. Febrile illness mapping-much of the world without data and without

393 evidence-based treatments. BMC Med. 2018;18(1):287. doi: 10.1186/s12916-020-01747-y.

394 12. Chandna A, Chew R, Shwe Nwe Htun N, Peto TJ, Zhang M, Liverani M, et al. Defining the

395 burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of

396 the Rural Febrile Illness project. Wellcome Open Res. 2022;6(64). doi:

397 10.12688/wellcomeopenres.16393.2.

398 13. Dittrich S, Tadesse BT, Moussy F, Chua A, Zorzet A, Tängden T, et al. Target Product Profile

399 for a Diagnostic Assay to Differentiate between Bacterial and Non-bacterial Infections and Reduce

400 Antimicrobial Overuse in Resource-Limited Settings: An Expert Consensus. PLoS One.

401 2016;11(8):e0161721. doi: 10.1371/journal.pone.0161721.

402 14. Jacobs L, Wong HR. Emerging infection and sepsis biomarkers: will they change current

403 therapies? Expert Rev Anti Infect Ther. 2016;14:929-41. doi: 10.1080/14787210.2016.1222272.

404 15. Chandna A, Aderie EM, Ahmad R, Arguni E, Ashley EA, Cope T, et al. Prediction of disease

405 severity in young children presenting with acute febrile illness in resource-limited settings: a

406 protocol for a prospective observational study. BMJ Open. 2021;11(1):e045826. doi:

407 10.1136/bmjopen-2020-045826.

408 16. Shrestha P, Dahal P, Ogbonnaa-Njoku C, Das D, Stepniewska K, Thomas NV, et al. Non-409 malarial febrile illness: a systematic review of published aetiological studies and case reports from 410 Southern Asia and South-eastern Asia, 1980–2015. BMC Med. 2020;18:299. doi: 10.1186/s12916- 411 020-01745-0.

412 17. Schenz J, Weigand MA, Uhle F. Molecular and biomarker-based diagnostics in early sepsis: 413 current challenges and future perspectives. Expert Rev Mol Diagn. 2019;19(12):1069-78. doi: 414 10.1080/14737159.2020.1680285.

415 18. Hopkins H, Bassat Q, Chandler CI, Crump JA, Feasey NA, Ferrand RA, et al. Febrile Illness

- 416 Evaluation in a Broad Range of Endemicities (FIEBRE): protocol for a multisite prospective
- 417 observational study of the causes of fever in Africa and Asia. BMJ Open. 2020;10(7):e035632. doi:

418 10.1136/bmjopen-2019-035632.

419 19. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv

420 Nurs. 2000;32(4):1008-15.

421 20. Varndell W, Fry M, Lutze M, D E. Use of the Delphi method to generate guidance in

422 emergency nursing practice: A systematic review. Int Emerg Nurs. 2021;56:100867. doi:

423 10.1016/j.ienj.2020.100867.

- 424 21. Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining
- 425 consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies. J

426 Clin Epidemiol. 2014;67:401-9. doi: 10.1016/j.jclinepi.2013.12.002.

427 22. Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: How to decide its

428 appropriateness. World J Methodol. 2021;11(4):116-29. doi: 10.5662/wjm.v11.i4.116.

429 23. Yun GW, CW T. Comparative Response to a Survey Executed by Post, E-mail, & Web Form. J

430 Compu-Mediated Com. 2000;6(1):JCMC613. doi: 10.1111/j.1083-6101.2000.tb00112.x.

- 431 24. Boel A, Navarro-Compán V, Landewé R, van der Heijde D. Two different invitation
- 432 approaches for consecutive rounds of a Delphi survey led to comparable final outcome. J Clin

433 Epidemiol. 2021;129:31-9. doi: 10.1016/j.jclinepi.2020.09.034.

434 25. Holey EA, Feeley JL, Dixon J, Whittaker VJ. An exploration of the use of simple statistics to

435 measure consensus and stability in Delphi studies. BMC Med Res Methodol. 2007;7:52. doi:

436 10.1186/1471-2288-7-52.

437 26. Osborn J, Roberts T, Guillen E, Bernal O, Roddy P, Ongarello S, et al. Prioritising pathogens 438 for the management of severe febrile patients to improve clinical care in low- and middle-income 439 countries. BMC Infect Dis. 2020;20:117. doi: 10.1186/s12879-020-4834-1.

440 27. The Academy of Medical Sciences, National Academy of Science and Technology Philippines.

441 Improving the development and deployment of diagnostics in Southeast Asia: Workshop report.

442 London, UK: 2019.

- 443 28. Khambhati K, Bhattacharjee G, Singh V. Current progress in CRISPR-based diagnostic
- 444 platforms. J Cell Biochem. 2019;120(3):2721-5. doi: 10.1002/jcb.27690.
- 445 29. Kraemer S, Vaught JD, Bock C, Gold L, Katilius E, Keeney TR, et al. From SOMAmer-Based
- 446 Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamline
- 447 Multiplex Proteomic Assay. PLoS One. 2011;6(10):e26332. doi: 10.1371/journal.pone.0026332.
- 448 30. Médicins San Frontières, Foundation for Innovative New Diagnostics, World Health
- 449 Organization. Target product profile (TPP) for a semi-open multiplex multi-analyte diagnostic
- 450 platform. Geneva, Switzerland: World Health Organization; 2018.

452 **FIGURE LEGENDS**

453

474 **Figure 3.** The top seven analytes, in descending order of priority based on sum of weighted scores, 475 which should be considered for inclusion in multiplex lateral flow rapid diagnostic tests for

482

489

Primary care: Adults

Figure 1

Primary care: Adults

Figure 2

Frequency

8

10

12

72

44

41

34

23

15

15

6

0

2

4

Secondary care: Children

Figure 3

А

C

Salmonella spp. (typhoidal) Antigen

Staphylococcus aureus Antigen

Dengue NS1 Antigen

C-reactive protein

Chikungunya IgM

Rickettsia spp. Antigen

Dengue IgM

Mainland Southeast Asia

Rank position 1 Rank position 2 Rank position 3 Rank position 4 Rank position 5

Figure 5